| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA800: Faricimab for treating wet age-related macular degeneration |
|
Medicine details |
|
| Medicine name | faricimab (Vabysmo®) |
| Formulation | 120 mg/ml intravitreal injection |
| Reference number | 4664 |
| Indication | Treatment of neovascular (wet) age related macular degeneration |
| Company | Roche Products Ltd |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/05/2022 |
| NICE guidance | TA800: Faricimab for treating wet age-related macular degeneration |
| Commercial arrangement | PAS |